Clinical trial
Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer…
NCT00174343 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00174343 |
|---|---|
| Title | Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients |
| Official title | Phase II Study Evaluating The Role Of Exemestane On Clinical And Pathologic Response Rates, And Its Aromatase Activity As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients. |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | exemestane (Aromasin®) |
| Enrollment | 46 |
| Start date | Nov 1, 2001 |
| Completion | Sep 1, 2006 |
| First posted | Sep 15, 2005 |
| Last update posted | Apr 22, 2011 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: